[Iatrogenes Kaposi-Sarkom unter Vedolizumab bei Colitis ulcerosa]

[Article in German]

Affiliations

¹ Klinik für Dermatologie und Phlebologie, Vivantes Klinikum im Friedrichshain, Berlin.
² Haut- und Laserzentrum Lichterfelde, Berlin.
³ Fachbereich Pathologie, Vivantes Klinikum Neukölln, Berlin.
⁴ Gastroenterologische Spezialpraxis, Berlin.

[Article in German]

Juliane Weilandt et al. J Dtsch Dermatol Ges. 2023 Apr.

. 2023 Apr:21 Suppl 2:22-24.

doi: 10.1111/ddg.15099_g.

¹ Klinik für Dermatologie und Phlebologie, Vivantes Klinikum im Friedrichshain, Berlin.
² Haut- und Laserzentrum Lichterfelde, Berlin.
³ Fachbereich Pathologie, Vivantes Klinikum Neukölln, Berlin.
⁴ Gastroenterologische Spezialpraxis, Berlin.

No abstract available

References

1. Esser S, Schöfer H, Hoffmann C, et al. S1-Leitlinie: Kaposi-Sarkom. J Dtsch Dermatol Ges. 2022;20(6):892-905.
1. Brambilla L, Maronese CA, Zelin E, et al. Kaposi's sarcoma, biologics and small molecules: Navigating the complex interplay between host immunity and viral biology. A case series with focused review of the literature. Dermatol Ther. 2022;35(3):e15278.
1. Papa V, Giustiniani MC, Lopetuso LR, Papa A. Human herpesvirus 8-associated colonic Kaposi's sarcoma during vedolizumab treatment in ulcerative colitis: a case report and review of the literature. BMC Gastroenterol. 2020;20(1):76.
1. Fischer AK, Kroesen A, Buttner R, Drebber U. [Kaposi sarcoma - a complication of treatment refractory ulcerative colitis]. Pathologie (Heidelb). 2022;43(5):372-376.
1. Ajao SO, Jayasingam R, Shaaban H. Iatrogenic Kaposi's sarcoma unmasked by Vedolizumab in a patient with ulcerative colitis and well-controlled human immunodeficiency virus: A case report. Int J Crit Illn Inj Sci. 2021;11(3):177-180.